<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm _content= 1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff= 20231005100804&amp;fc=20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231005100804&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 10 月 5 日星期四 14:08:12 +0000</lastbuilddate><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>非牙科侵入性手术和感染性心内膜炎的风险：重新审视的时间：美国心脏协会的科学建议</title><link/>https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>目前尚无已发表的前瞻性随机临床试验表明：(1) 确定了侵入性牙科和非牙科侵入性操作与感染性心内膜炎风险之间的关联；或 (2) 明确了在侵入性操作中使用抗生素预防的有效性和安全性预防高危患者感染性心内膜炎。此外，之前的观察性研究检验了非牙科侵入性操作与...的关系。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 5 日。doi：10.1161/CIR.0000000000001180。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目前尚无已发表的前瞻性随机临床试验表明：(1) 确定了侵入性牙科和非牙科侵入性操作与感染性心内膜炎风险之间的关联；或 (2) 明确了在侵入性操作中使用抗生素预防的有效性和安全性预防高危患者感染性心内膜炎。此外，之前检查非牙科侵入性操作与感染性心内膜炎风险之间关系的观察性研究因样本量不足而受到限制。他们通常关注一些潜在的高危人群然而，瑞典和英国最近使用全国数据库进行的调查表明，非牙科侵入性操作与感染性心内膜炎的后续发展（特别是感染性心内膜炎的高危患者）之间存在关联，促进了这一发展当前的科学咨询。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37795631</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001180>10.1161/CIR.0000000000001180</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37795631</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>拉里·M·巴杜尔</dc:creator><dc:creator>伊姆雷·詹斯基</dc:creator><dc:creator>马丁·H·桑希尔</dc:creator><dc:creator>泽瑞尔达·埃斯奎尔·加里戈斯</dc:creator><dc:creator>丹尼尔·C·德西蒙</dc:creator><dc:creator>凯伦·韦尔蒂-沃尔夫</dc:creator><dc:creator>安妮特·L·贝克</dc:creator><dc:creator>琼斯佩妮</dc:creator><dc:creator>伯纳德·普伦德加斯特</dc:creator><dc:creator>马克·J·戴尔</dc:creator><dc:creator>美国心脏协会终身先天性心脏病和年轻人心脏健康委员会以及心血管和中风护理委员会</dc:creator><dc:date>2023-10-05</dc:date><dc:source>循环</dc:source><dc:title>非牙科侵入性手术和感染性心内膜炎的风险：重新审视的时间：美国心脏协会的科学建议</dc:title><dc:identifier>下午:37795631</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001180</dc:identifier></item><item><title> HLHS 儿童的纵向随访以及诺伍德分流类型与长期结果之间的关联：SVRIII 研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>结论：到诺伍德手术后 12 年，分流类型与 RVEF、峰值 Vo(2)、并发症发生率和无移植生存率的相关性极小。在接受 CMR 评估的幸存者亚组中，RVEF 得到保留。生存率、运动表现不佳和发病率不断上升，凸显了需要创新策略来改善左心发育不全综合征患者的长期预后。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 5 日。doi：10.1161/CIRCULATIONAHA.123.065192。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：在 SVR 试验（单心室重建）中，患有左心发育不良综合征的新生儿在诺伍德手术中被随机分配接受改良的 Blalock-Taussig-Thomas 分流术 (mBTTS) 或右心室至肺动脉分流术 (RVPAS) RVPAS 组在 1 年时的无移植生存率较高，但在 6 年时治疗组的无移植生存率不再有差异；两个治疗组都积累了重要的发病率。在该队列的第三次随访中（SVRIII [长期结果患有左心发育不良综合征的儿童和诺伍德分流类型的影响]），我们测量了 12 岁的纵向结果及其风险因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过记录审查和电话访谈收集年度病史。对患有 Fontan 生理学的参与者在 10 至 14 岁时进行心脏磁共振成像 (CMR)、超声心动图和自行车测功心肺运动测试。生存率和并发症发生率（例如，心律失常或蛋白质丢失性肠病）在 12 岁之前确定。主要研究结果是通过 CMR 测得的右心室射血分数 (RVEF)，主要分析根据收到的分流类型进行。多变量线性和通过 CMR 和 Fontan 移植后生存率创建 RVEF 的 Cox 回归模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在参加 SVR 的 549 名参与者中，313 名（76%；60.7% 男性）无移植幸存者中的 237 名（mBTTS，147 名中的 105 名；RVPAS，161 名中的 129 名；均为 5 名中的 3 名）参加了 SVRIII。根据 CMR 计算的 RVEF分流组的情况相似（RVPAS，51±9.6 [n=90]，mBTTS，52±7.4 [n=75]； <i>P</i> = 0.43）。RVPAS 和 mBTTS 组的无移植生存率没有差异 12年龄（分别为 277 人中的 163 人 [59%] 与 267 人中的 144 人 [54%]； <i>P</i> = 0.11），年龄和性别的预测峰值 Vo <sub>2</sub>百分比（74±18% [n=91] 与 72±18） % [n=84]； <i>P</i> =0.71），或按体型和性别预测工作率的百分比（65±20% 与 64±19%； <i>P</i> =0.65）。RVPAS 组与 mBTTS 组相比，蛋白质累积发生率更高肠病（5% vs 2%； <i>P</i> = 0.04）和导管干预（每 100 患者年 14 例 vs 10 例； <i>P</i> = 0.01）消失，但其他并发症的发生率相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：到 Norwood 手术后 12 年，分流类型与 RVEF、峰值 Vo <sub>2</sub> 、并发症发生率和无移植生存率的相关性极小。在接受 CMR 评估的幸存者亚组中，RVEF 得到保留。低无移植生存率，运动表现不佳和不断增加的发病率凸显了需要创新策略来改善左心发育不全综合征患者的长期预后。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT00115934。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37795623</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065192>10.1161/CIRCULATIONAHA.123.065192</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37795623</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>卡伦·戈德堡</dc:creator><dc:creator>费利西亚·特拉亨伯格</dc:creator><dc:creator>J·威廉·盖纳</dc:creator><dc:creator>威廉·T·马勒</dc:creator><dc:creator>奇特拉·拉维尚卡</dc:creator><dc:creator>史蒂文·M·施瓦茨</dc:creator><dc:creator>詹姆斯·F·克诺塔</dc:creator><dc:creator>理查德·G·奥耶</dc:creator><dc:creator>拉塞尔·贡维尔</dc:creator><dc:creator>迈克尔·泰勒</dc:creator><dc:creator>史蒂芬·帕里登</dc:creator><dc:creator>彼得·C·弗罗梅尔特</dc:creator><dc:creator>凯瑟琳·阿夫顿</dc:creator><dc:creator>安德鲁·M·阿兹</dc:creator><dc:creator>克里斯汀·M·伯恩斯</dc:creator><dc:creator>乔恩·德特里奇</dc:creator><dc:creator>凯文·D·希尔</dc:creator><dc:creator>安东尼奥·G·卡布雷拉</dc:creator><dc:creator>艾伦·B·刘易斯</dc:creator><dc:creator>克里斯蒂安·皮萨罗</dc:creator><dc:creator>阿米·沙阿</dc:creator><dc:creator>比努·夏尔马</dc:creator><dc:creator>简·W·纽伯格</dc:creator><dc:creator>儿科心脏网络调查员</dc:creator><dc:date>2023-10-05</dc:date><dc:source>循环</dc:source><dc:title>HLHS 儿童的纵向随访以及诺伍德分流类型与长期结果之间的关联：SVRIII 研究</dc:title><dc:identifier>下午:37795623</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065192</dc:identifier></item><item><title>心绞痛且无阻塞性冠状动脉疾病患者的侵入性内分型：一项随机对照试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>结论：对于心绞痛且冠状动脉无阻塞的患者，侵入性功能评估的诊断对长期心绞痛负担没有影响，而治疗满意度有所提高。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 5 日。doi：10.1161/CIRCULATIONAHA.123.064751。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：我们研究了侵入性冠状动脉功能测试对于诊断无阻塞冠状动脉患者心绞痛原因的有用性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对英国3家医院转诊进行冠状动脉CT血管造影的门诊患者进行前瞻性筛查。冠状动脉CT血管造影后，冠状动脉通畅且同意的患者接受侵入性内分型。诊断评估包括冠状动脉造影、血流储备分数（如果≤0.80，则排除患者），对于没有阻塞性冠状动脉疾病的患者，还需检查冠状动脉血流储备（异常&lt;2.0）、微血管阻力指数（异常≥25）和冠状动脉内输注乙酰胆碱（0.182、1.82和18.2μg） /mL；2 mL/min，持续 2 分钟）以评估微血管和冠状动脉痉挛。参与者被随机分配向侵入性心脏病专家披露冠状动脉功能测试结果（干预组）或不披露（对照组，盲法）。在对照组中，血管舒缩性心绞痛的诊断基于病史、无创检查和冠状动脉造影。主要结果是基于冠状动脉计算机断层扫描的初始诊断的重新分类率与最终诊断的重新分类率的组间差异。侵入性内分型后诊断。西雅图心绞痛问卷总结评分和药物治疗满意度调查问卷是次要结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 322 名符合条件的患者中，250 名（77.6%）接受了侵入性内分型；19 名（7.6%）患有阻塞性冠状动脉疾病，127 名（55.0%）患有微血管心绞痛，27 名（11.7%）患有血管痉挛性心绞痛，17 名（7.4%）患有血管性心绞痛。两者皆有，60 例 (26.0%) 无异常。共有 231 例患者（平均年龄，55.7 岁；64.5% 女性）被随机分配并随访（中位持续时间，19.9 [12.6-26.9] 个月）。临床医生诊断干预组有 51 名 (44.3%) 患者出现血管舒缩性心绞痛，对照组有 55 名 (47.4%) 患者出现血管舒缩性心绞痛。随机化后，干预组患者出现血管舒缩性心绞痛的比例是 4 倍（比值比，4.05 [95% CI，2.32- 7.24]； <i>P</i> &lt;0.001）更有可能被诊断为冠状动脉血管舒缩障碍；该诊断的频率增加至 76.5%。随机分组前，各组之间冠状动脉功能正常（即无血管舒缩障碍）的频率没有差异（ 51.3% 对比 50.9%），但随机化后干预组有所下降（23.5% 对比 50.9%， <i>P</i> &lt;0.001）。在 6 个月和 12 个月时，干预组与对照组的西雅图心绞痛问卷总分分别为 59.2±24.2（相对于基线的变化为 2.3±16.2）与 60.4±23.9（4.6±16.4 变化）和 63.7±23.5（4.7±14.7 变化）与 66.0±19.3（7.9±17.1 变化），组间无差异（总体<i>P</i> =0.36） ).与对照组相比，干预组12个月时总体治疗满意度较高（69.9±22.8 vs 61.7±26.9， <i>P</i> =0.013）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：对于心绞痛且冠状动脉无阻塞的患者，侵入性功能评估的诊断对长期心绞痛负担没有影响，而治疗满意度有所提高。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">注册：网址：https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验：gov；唯一标识符：NCT03477890。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37795617</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064751>10.1161 / CIRCULATIONAHA.123.064751</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37795617</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>诺瓦利亚·P·西迪克</dc:creator><dc:creator>贝瑟尼·斯坦利</dc:creator><dc:creator>罗伯特赛克斯</dc:creator><dc:creator>安德鲁·J·莫罗</dc:creator><dc:creator>康纳·P·布拉德利</dc:creator><dc:creator>迈克尔·麦克德莫特</dc:creator><dc:creator>托马斯·J·福特</dc:creator><dc:creator>吉尔斯·罗迪蒂</dc:creator><dc:creator>阿利斯特·哈格里夫斯</dc:creator><dc:creator>大卫·斯托博</dc:creator><dc:creator>杰奎琳·亚当斯</dc:creator><dc:creator>约翰·伯恩</dc:creator><dc:creator>艾哈迈德·马鲁斯</dc:creator><dc:creator>罗宾·杨</dc:creator><dc:creator>大卫·卡里克</dc:creator><dc:creator>罗斯·麦克吉奇</dc:creator><dc:creator>大卫·科科伦</dc:creator><dc:creator>尼尼安·朗</dc:creator><dc:creator>罗伯特·赫吉</dc:creator><dc:creator>吴奥莉维亚</dc:creator><dc:creator>玛格丽特·B·麦恩特加特</dc:creator><dc:creator>亚历克斯·麦康纳奇</dc:creator><dc:creator>科林·贝瑞</dc:creator><dc:date>2023-10-05</dc:date><dc:source>循环</dc:source><dc:title>心绞痛且无阻塞性冠状动脉疾病患者的侵入性内分型：一项随机对照试验</dc:title><dc:identifier>下午：37795617</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064751</dc:identifier></item><item><title>睡眠慢波的听觉刺激可增强人类的左心室功能</title><link/>https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 5 日：ehad630。doi：10.1093/eurheartj/ehad630。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37794725</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad630>10.1093/eurheartj/ehad630</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37794725</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>斯蒂芬妮·休维勒</dc:creator><dc:creator>曼努埃尔·卡罗·多明格斯</dc:creator><dc:creator>法比亚·M·斯蒂奇</dc:creator><dc:creator>罗塞拉萨拉</dc:creator><dc:creator>弗洛朗·阿兹里</dc:creator><dc:creator>安娜·特里佩尔</dc:creator><dc:creator>塔贝亚·瑞夫</dc:creator><dc:creator>苏珊·马肯多夫</dc:creator><dc:creator>大卫·尼德塞尔</dc:creator><dc:creator>菲利普·博姆</dc:creator><dc:creator>格洛丽亚·斯托尔</dc:creator><dc:creator>莉莉·劳布舍尔</dc:creator><dc:creator>杰维卡·泰万</dc:creator><dc:creator>克里斯蒂娜·M·斯宾格勒</dc:creator><dc:creator>乔安娜·加维内卡</dc:creator><dc:creator>埃琳娜·奥斯托</dc:creator><dc:creator>雷托·胡贝尔</dc:creator><dc:creator>妮可·温德罗斯</dc:creator><dc:creator>克里斯蒂安·施密德</dc:creator><dc:creator>卡罗琳·卢斯坦伯格</dc:creator><dc:date>2023-10-05</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>睡眠慢波的听觉刺激可增强人类的左心室功能</dc:title><dc:identifier>下午:37794725</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad630</dc:identifier></item><item><title>元临床时代初期的医学</title><link/>https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 5 日：ehad599。doi：10.1093/eurheartj/ehad599。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37794638</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad599>10.1093/eurheartj/ehad599</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37794638</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>帕诺斯·瓦尔达斯</dc:creator><dc:creator>埃马努伊·瓦尔达斯</dc:creator><dc:creator>斯蒂利亚诺斯·蔡斯</dc:creator><dc:date>2023-10-05</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>元临床时代初期的医学</dc:title><dc:identifier>下午:37794638</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad599</dc:identifier></item><item><title>当技术创新成为经济危机国家治疗患者的唯一途径时：叙利亚的经验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 5 日：ehad634。doi：10.1093/eurheartj/ehad634。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37794637</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad634>10.1093/eurheartj/ehad634</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37794637</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>阿姆鲁·阿卜丁</dc:creator><dc:creator>阿西姆·卡特贝</dc:creator><dc:creator>亚辛·巴尼·玛吉</dc:creator><dc:date>2023-10-05</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>当技术创新成为经济危机国家治疗患者的唯一途径时：叙利亚的经验</dc:title><dc:identifier>下午:37794637</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad634</dc:identifier></item><item><title>迈向个性化心血管护理：全球急性冠脉事件登记系统 3.0 评分预示着人工智能时代</title><link/>https://pubmed.ncbi.nlm.nih.gov/37794616/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 5 日：ehad597。doi：10.1093/eurheartj/ehad597。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37794616/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37794616</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad597>10.1093/eurheartj/ehad597</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37794616</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>弗洛里安·温兹尔</dc:creator><dc:creator>基思·AA·福克斯</dc:creator><dc:creator>托马斯·F·卢舍尔</dc:creator><dc:date>2023-10-05</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>迈向个性化心血管护理：全球急性冠脉事件登记系统 3.0 评分预示着人工智能时代</dc:title><dc:identifier>下午:37794616</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad597</dc:identifier></item><item><title>临床 CRISPR-Cas9 工程 T 细胞中染色体丢失的减轻</title><link/>https://pubmed.ncbi.nlm.nih.gov/37794590/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description> CRISPR-Cas9基因组编辑使先进的T细胞疗法成为可能，但目标染色体的偶尔丢失仍然是一个安全问题。为了研究Cas9诱导的染色体丢失是否是一种普遍现象并评估其临床意义，我们对原代人类进行了系统分析T 细胞。阵列和汇集的 CRISPR 筛选显示，染色体丢失在整个基因组中普遍存在，并导致目标染色体部分和全部丢失，包括...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 27 日：S0092-8674(23)00975-3. doi: 10.1016/j.cell.2023.08.041. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CRISPR-Cas9基因组编辑使先进的T细胞疗法成为可能，但目标染色体的偶尔丢失仍然是一个安全问题。为了研究Cas9诱导的染色体丢失是否是一种普遍现象并评估其临床意义，我们对原代人类进行了系统分析T 细胞。阵列和汇集的 CRISPR 筛选显示，染色体丢失在整个基因组中普遍存在，并导致目标染色体部分和全部丢失，包括在临床前嵌合抗原受体 T 细胞中。染色体丢失的 T 细胞在培养中持续数周，这意味着干扰临床使用的潜力。我们首次对 Cas9 工程化 T 细胞 (NCT03399448) 进行人体临床试验时采用了改良的细胞制造工艺，减少了染色体丢失，同时在很大程度上保留了基因组编辑功效。p53 的表达与保护相关从该协议中观察到的染色体丢失中，表明了 T 细胞工程的机制和策略，可以减轻临床中的这种遗传毒性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37794590/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37794590</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.041>10.1016/j.cell.2023.08.041</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37794590</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>康纳·土田</dc:creator><dc:creator>纳达夫·布兰德斯</dc:creator><dc:creator>雷蒙德·布埃诺</dc:creator><dc:creator>特立尼达玛丽娜</dc:creator><dc:creator>托马斯·马宗德</dc:creator><dc:creator>于冰飞</dc:creator><dc:creator>黄秉珍</dc:creator><dc:creator>克里斯托弗·张</dc:creator><dc:creator>刘嘉敏</dc:creator><dc:creator>孙阳</dc:creator><dc:creator>凯特琳·R·霍普金斯</dc:creator><dc:creator>凯文·帕克</dc:creator><dc:creator>齐艳艳</dc:creator><dc:creator>劳拉·霍夫曼</dc:creator><dc:creator>安苏曼·T·萨帕蒂</dc:creator><dc:creator>爱德华·施塔特莫尔</dc:creator><dc:creator>杰米高清美食</dc:creator><dc:creator>贾斯汀·艾肯</dc:creator><dc:creator>约瑟夫·弗莱埃塔</dc:creator><dc:creator>卡尔·H·琼</dc:creator><dc:creator>霍华德·张</dc:creator><dc:creator>叶春吉米</dc:creator><dc:creator>詹妮弗·杜德纳</dc:creator><dc:date>2023-10-05</dc:date><dc:source>细胞</dc:source><dc:title>临床 CRISPR-Cas9 工程 T 细胞中染色体丢失的减轻</dc:title><dc:identifier>下午:37794590</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.041</dc:identifier></item><item><title> SND1结合SARS-CoV-2负义RNA并通过NSP9促进病毒RNA合成</title><link/>https://pubmed.ncbi.nlm.nih.gov/37794589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>病毒 RNA 生物发生的调节是高效 SARS-CoV-2 感染的基础。为了表征参与此过程的宿主 RNA 结合蛋白 (RBP)，我们通过生化方法鉴定了与基因组和亚基因组 SARS-CoV-2 RNA 结合的蛋白质。我们发现宿主蛋白 SND1 结合负义病毒 RNA 的 5&#39; 端，是 SARS-CoV-2 RNA 合成所必需的。SND1 耗尽的细胞形成较小的复制细胞器，并表现出病毒生长动力学减弱。我们发现 NSP9，一种.. 。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 28 日：S0092-8674(23)00980-7. doi: 10.1016/j.cell.2023.09.002. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">病毒 RNA 生物发生的调节是高效 SARS-CoV-2 感染的基础。为了表征参与此过程的宿主 RNA 结合蛋白 (RBP)，我们通过生化方法鉴定了与基因组和亚基因组 SARS-CoV-2 RNA 结合的蛋白质。我们发现宿主蛋白 SND1 结合负义病毒 RNA 的 5&#39; 端，是 SARS-CoV-2 RNA 合成所必需的。SND1 耗尽的细胞形成较小的复制细胞器，并表现出病毒生长动力学减弱。我们发现 NSP9，一种病毒 RBP和直接的 SND1 相互作用伴侣，与感染过程中产生的正义和负义 RNA 的 5&#39; 端共价连​​接。这些连接发生在复制转录起始位点，与 NSP9 启动病毒 RNA 合成一致。从机制上讲，SND1 重塑 NSP9 占据并改变 NSP9 与病毒 RNA 中起始核苷酸的共价连接。我们的研究结果表明 NSP9 参与了 SARS-CoV-2 RNA 合成的启动，并揭示了细胞蛋白在协调病毒 RNA 生产中的意想不到的作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37794589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37794589</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.002>10.1016/j.cell.2023.09.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37794589</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator>诺拉·施密特</dc:creator><dc:creator>萨宾娜·甘斯基</dc:creator><dc:creator>魏元杰</dc:creator><dc:creator>亚历山大·加贝尔</dc:creator><dc:creator>塞巴斯蒂安·齐林斯基</dc:creator><dc:creator>哈斯米克·克什什安</dc:creator><dc:creator>迦勒·拉罗</dc:creator><dc:creator>丽芙·齐默尔曼</dc:creator><dc:creator>贾娜·马克罗奇奥娃</dc:creator><dc:creator>节奏皮尔斯</dc:creator><dc:creator>卡斯滕·克雷</dc:creator><dc:creator>托马斯·亨尼格</dc:creator><dc:creator>塞巴斯蒂安·施泰格迈尔</dc:creator><dc:creator>兰伯特·莫永</dc:creator><dc:creator>马克·霍拉彻</dc:creator><dc:creator>西蒙娜·维尔纳</dc:creator><dc:creator>延斯·艾丁</dc:creator><dc:creator>马可·奥尔金-纳瓦</dc:creator><dc:creator>拉姆亚·波塔巴图拉</dc:creator><dc:creator>阿努贾·基贝</dc:creator><dc:creator>拉尔斯·多尔肯</dc:creator><dc:creator>雷蒙德·P·史密斯</dc:creator><dc:creator>涅瓦卡利斯坎</dc:creator><dc:creator>安娜莉莎·马尔斯科</dc:creator><dc:creator>克里斯汀·克雷普尔</dc:creator><dc:creator>约亨·博登</dc:creator><dc:creator>安德烈亚斯·皮克迈尔</dc:creator><dc:creator>史蒂文·A·卡尔</dc:creator><dc:creator>彼得·奇兰达</dc:creator><dc:creator>弗洛里安·艾哈德</dc:creator><dc:creator>马蒂亚斯·蒙肖尔</dc:creator><dc:date>2023-10-05</dc:date><dc:source>细胞</dc:source><dc:title>SND1结合SARS-CoV-2负义RNA并通过NSP9促进病毒RNA合成</dc:title><dc:identifier>下午:37794589</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.002</dc:identifier></item><item><title>撤回：在初级卫生保健单位通过 Stop-Bang 和 Epworth 嗜睡量表筛查阻塞性睡眠呼吸暂停高风险年轻人的心血管风险概况</title><link/>https://pubmed.ncbi.nlm.nih.gov/37793986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 5 日：ehad580。doi：10.1093/eurheartj/ehad580。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37793986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793986</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad580>10.1093/eurheartj/ehad580</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37793986</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:date> 2023-10-04</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>撤回：在初级卫生保健单位通过 Stop-Bang 和 Epworth 嗜睡量表筛查阻塞性睡眠呼吸暂停高风险年轻人的心血管风险概况</dc:title><dc:identifier>下午:37793986</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad580</dc:identifier></item><item><title> KDIGO 或 UACR：哪个是影响 SGLT2i 对心力衰竭患者疗效的关键？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 10 日；82(15):e135-e136.doi: 10.1016/j.jacc.2023.06.051。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37793755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793755</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.051>10.1016/j.jacc.2023.06.051</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37793755</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>徐晓群</dc:creator><dc:creator>朱厚勇</dc:creator><dc:creator>龙菜</dc:creator><dc:creator>陈铁龙</dc:creator><dc:creator>林凯庆</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>KDIGO 或 UACR：哪个是影响 SGLT2i 对心力衰竭患者疗效的关键？</dc:title><dc:identifier>下午：37793755</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.051</dc:identifier></item><item><title>恩格列净治疗心力衰竭患者：不同肾脏风险类别的疗效和安全性问题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37793754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 10 日；82(15):e133.doi:10.1016/j.jacc.2023.06.052。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37793754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793754</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.052>10.1016/j.jacc.2023.06.052</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37793754</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>大城结弦</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>恩格列净治疗心力衰竭患者：不同肾脏风险类别的疗效和安全性问题</dc:title><dc:identifier>下午:37793754</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.052</dc:identifier></item><item><title>家族性高胆固醇血症儿童筛查：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37793753/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>儿童期家族性高胆固醇血症 (FH) 筛查仍存在争议。尽管人们普遍同意证据和缺乏证据的领域，包括缺乏长期临床试验证明筛查和筛查可减少冠心病事件，但现有指南提供了相互矛盾的建议。关于他汀类药物副作用的长期数据。现有循证框架的局限性是依赖 1 个证据分级系统来确定…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 10 日；82(15):1558-1563.doi:10.1016/j.jacc.2023.07.028。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">儿童期家族性高胆固醇血症 (FH) 筛查仍存在争议。尽管人们普遍同意证据和缺乏证据的领域，包括缺乏长期临床试验证明筛查和筛查可减少冠心病事件，但现有指南提供了相互矛盾的建议。关于他汀类药物副作用的长期数据。现有循证框架的局限性是依赖 1 证据分级系统来确定建议。然而，存在与 FH 相关的严格证据评估替代方案。FH 被认为是 1 级遗传病，这意味着识别和治疗将改善受影响者的健康结果。低密度脂蛋白胆固醇升高是 FH 的主要后果，可被认为是动脉粥样硬化和冠心病的原因。将这些概念纳入现有证据途径可以纳入替代临床试验结果（低密度脂蛋白胆固醇降低和动脉粥样硬化消退）和用药安全性观察数据，加强了儿科 FH 筛查的证据。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37793753/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793753</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.028>10.1016/j.jacc.2023.07.028</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37793753</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>塞缪尔·吉丁</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>家族性高胆固醇血症儿童筛查：JACC 本周评论主题</dc:title><dc:identifier>下午：37793753</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.028</dc:identifier></item><item><title>缺血性中风一级和二级预防的抗血栓治疗：JACC 最先进的综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37793752/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>中风是一种毁灭性的疾病，在世界范围内具有很高的发病率和死亡率。抗血栓治疗在中风事件的一级和二级预防中都发挥着至关重要的作用。对于大动脉粥样硬化和小血管疾病，通常首选单一或双重抗血小板治疗，而在血瘀或高凝状态（大多数情况下会导致红色血栓）的情况下，建议进行抗凝治疗。然而，抗血栓治疗的益处必须... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 10 日；82(15):1538-1557.doi:10.1016/j.jacc.2023.07.025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">中风是一种毁灭性的疾病，在世界范围内具有很高的发病率和死亡率。抗血栓治疗在中风事件的一级和二级预防中都发挥着至关重要的作用。对于大动脉粥样硬化和小血管疾病，通常首选单一或双重抗血小板治疗，而在血瘀或高凝状态（主要导致红色血栓）的情况下，建议进行抗凝治疗。然而，必须权衡抗血栓治疗的益处与出血风险的增加，这可能对这种情况的药物治疗带来重大挑战。这篇综述全面总结了当前关于缺血性中风抗血栓治疗的现有证据，并概述了更新的治疗算法，以支持医生根据个体患者和中风的潜在机制制定策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37793752/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793752</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.025>10.1016/j.jacc.2023.07.025</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37793752</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>安东尼奥·格雷科</dc:creator><dc:creator>乔瓦尼·奥奇平蒂</dc:creator><dc:creator>丹尼尔·贾科波</dc:creator><dc:creator>费代丽卡·阿涅洛</dc:creator><dc:creator>克劳迪奥·劳达尼</dc:creator><dc:creator>马可·斯帕格诺洛</dc:creator><dc:creator>玛丽亚·萨拉·毛罗</dc:creator><dc:creator>卡拉·罗奇拉</dc:creator><dc:creator>西蒙娜·菲诺基亚罗</dc:creator><dc:creator>普拉西多·玛丽亚·马佐内</dc:creator><dc:creator>丹尼斯·克里斯蒂安娜·法鲁</dc:creator><dc:creator>大卫·兰多利纳</dc:creator><dc:creator>尼古拉·阿米拉比莱</dc:creator><dc:creator>安东尼诺·因贝西</dc:creator><dc:creator>卡梅罗·拉福</dc:creator><dc:creator>达维德·卡波丹诺</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>缺血性中风一级和二级预防的抗血栓治疗：JACC 最先进的综述</dc:title><dc:identifier>下午：37793752</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.025</dc:identifier></item><item><title>通过超声心动图对法布里心肌病进行分期：回到根源？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 10 日；82(15):1535-1537.doi:10.1016/j.jacc.2023.08.009。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37793751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793751</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.009>10.1016/j.jacc.2023.08.009</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37793751</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>基尔·桑德·普拉斯曼</dc:creator><dc:creator>森塔格拉夫</dc:creator><dc:creator>康斯坦丁·盖特勒</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>通过超声心动图对法布里心肌病进行分期：回到根源？</dc:title><dc:identifier>下午:37793751</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.009</dc:identifier></item><item><title>法布里病患者心脏损伤程度的预后意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/37793750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231005100804&amp;v=2.17.9.post6+86293ac<description>结论：在 FD 患者中，通过超声心动图评估的新型心脏损害分期分类与心血管结局密切相关，可能有助于完善风险分层。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 10 月 10 日；82(15):1524-1534.doi:10.1016/j.jacc.2023.07.026。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：关于法布里病（FD）患者心血管结局风险分层的证据有限。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究试图根据超声心动图评估的心脏损伤程度将 FD 患者分为疾病阶段，并评估其在多中心队列中的预后影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：来自 5 个意大利转诊中心的 FD 患者被分为 4 个阶段：0 期，无心脏受累；1 期，左心室 (LV) 肥厚（LV 最大壁厚度 >;12 mm）；2 期，左心房 (LA)扩大（LA 体积指数 >;34 mL/m <sup>2</sup> ）；3 期，心室功能不全（左室射血分数 &lt;50% 或 E/e&#39; ≥15 或 TAPSE &lt;17 mm）。研究终点是全因死亡的复合终点、因心力衰竭、新发房颤、严重缓慢性心律失常或快速性心律失常以及缺血性中风而住院。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共纳入314例患者，其中0期174例（56%），1期41例（13%），2期57例（18%），3期42例（13%）随着心脏损伤分期的恶化，观察到 8 年复合事件发生率逐渐增加（对数秩 P &lt; 0.001）。在多变量 Cox 回归分析中，分期与心血管事件风险独立相关（HR：2.086/ 1 阶段增加；95% CI：1.487-2.927；P &lt; 0.001）。值得注意的是，与左室肥厚程度相比，心脏分期显示出更强的附加预后价值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在 FD 患者中，通过超声心动图评估的新型心脏损害分期分类与心血管结局密切相关，可能有助于完善风险分层。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37793750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793750</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.026>10.1016/j.jacc.2023.07.026</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37793750</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator>玛丽亚·基亚拉·梅乌奇</dc:creator><dc:creator>罗莎·利洛</dc:creator><dc:creator>安娜玛丽亚·德尔·弗朗哥</dc:creator><dc:creator>埃马努埃莱·蒙达</dc:creator><dc:creator>朱莉娅·伊纳科内</dc:creator><dc:creator>里卡多·巴尔达萨雷</dc:creator><dc:creator>费德里科·迪·尼古拉</dc:creator><dc:creator>万达帕里西</dc:creator><dc:creator>安东内拉·隆巴尔多</dc:creator><dc:creator>莱蒂齐亚·斯皮内利</dc:creator><dc:creator>埃琳娜·比亚吉尼</dc:creator><dc:creator>毛里齐奥·皮耶罗尼</dc:creator><dc:creator>安东尼奥·皮萨尼</dc:creator><dc:creator>菲利波·克雷亚</dc:creator><dc:creator>吉多·亚卡里诺</dc:creator><dc:creator>朱塞佩·利蒙格利</dc:creator><dc:creator>亚科波·奥利沃托</dc:creator><dc:creator>弗朗西斯卡·格拉齐亚尼</dc:creator><dc:date>2023-10-04</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>法布里病患者心脏损伤程度的预后意义</dc:title><dc:identifier>下午:37793750</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.026</dc:identifier></item><item><title>循环死亡后的捐赠：改变心脏移植的模式</title><link/>https://pubmed.ncbi.nlm.nih.gov/37793749/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231005100804&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 10;82(15):1521-1523. doi: 10.1016/j.jacc.2023.08.025.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793749/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793749</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.025>10.1016/j.jacc.2023.08.025</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793749</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Sean P Pinney</dc:creator><dc:creator> Maria Rosa Costanzo</dc:creator><dc:date> 2023-10-04</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Donation After Circulatory Death: Shifting the Paradigm in Heart Transplantation</dc:title><dc:identifier> pmid:37793749</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.025</dc:identifier></item><item><title> Outcomes of Heart Transplant Donation After Circulatory Death</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793748/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231005100804&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: In the largest single-center comparison of DCD and DBD heart transplantations to date, outcomes among DCD recipients are noninferior to those of DBD recipients. This study adds to the published data supporting DCD donors as a safe means to expand the heart donor pool. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 10;82(15):1512-1520. doi: 10.1016/j.jacc.2023.08.006.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Heart transplantation using donation after circulatory death (DCD) allografts is increasingly common, expanding the donor pool and reducing transplant wait times. However, data remain limited on clinical outcomes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: We sought to compare 6-month and 1-year clinical outcomes between recipients of DCD hearts, most of them recovered with the use of normothermic regional perfusion (NRP), and recipients of donation after brain death (DBD) hearts. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We conducted a single-center retrospective observational study of all adult heart-only transplants from January 2020 to January 2023. Recipient and donor data were abstracted from medical records and the United Network for Organ Sharing registry, respectively. Survival analysis and Cox regression were used to compare the groups. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: During the study period, 385 adults (median age 57.4 years [IQR: 48.0-63.7 years]) underwent heart-only transplantation, including 122 (32%) from DCD donors, 83% of which were recovered with the use of NRP. DCD donors were younger and had fewer comorbidities than DBD donors. DCD recipients were less often hospitalized before transplantation and less likely to require pretransplantation temporary mechanical circulatory support compared with DBD recipients. There were no significant differences between groups in 1-year survival, incidence of severe primary graft dysfunction, treated rejection during the first year, or likelihood of cardiac allograft vasculopathy at 1 year after transplantation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In the largest single-center comparison of DCD and DBD heart transplantations to date, outcomes among DCD recipients are noninferior to those of DBD recipients. This study adds to the published data supporting DCD donors as a safe means to expand the heart donor pool.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793748/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793748</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.006>10.1016/j.jacc.2023.08.006</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793748</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Hasan K Siddiqi</dc:creator><dc:creator> John Trahanas</dc:creator><dc:creator> Meng Xu</dc:creator><dc:creator> Quinn Wells</dc:creator><dc:creator> Eric Farber-Eger</dc:creator><dc:creator> Chetan Pasrija</dc:creator><dc:creator> Kaushik Amancherla</dc:creator><dc:creator> Alexandra Debose-Scarlett</dc:creator><dc:creator> D Marshall Brinkley</dc:creator><dc:creator> JoAnn Lindenfeld</dc:creator><dc:creator> Jonathan N Menachem</dc:creator><dc:creator> Henry Ooi</dc:creator><dc:creator> Dawn Pedrotty</dc:creator><dc:creator> Lynn Punnoose</dc:creator><dc:creator> Aniket S Rali</dc:creator><dc:creator> Suzanne Sacks</dc:creator><dc:creator> Mark Wigger</dc:creator><dc:creator> Sandip Zalawadiya</dc:creator><dc:creator> William McMaster</dc:creator><dc:creator> Steven Devries</dc:creator><dc:creator> Ashish Shah</dc:creator><dc:creator> Kelly Schlendorf</dc:creator><dc:date> 2023-10-04</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Outcomes of Heart Transplant Donation After Circulatory Death</dc:title><dc:identifier> pmid:37793748</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.006</dc:identifier></item><item><title> The Pooled Cohort Equations and the Test of Time</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793747/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231005100804&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 10;82(15):1509-1511. doi: 10.1016/j.jacc.2023.08.024.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793747/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793747</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.024>10.1016/j.jacc.2023.08.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793747</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Donald M Lloyd-Jones</dc:creator><dc:date> 2023-10-04</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> The Pooled Cohort Equations and the Test of Time</dc:title><dc:identifier> pmid:37793747</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.024</dc:identifier></item><item><title> Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231005100804&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: The PCE performed well in a community cohort representing real-world clinical practice. Values outside PCE ranges and initiation of statin medication did not affect performance. These results have implications for the applicability of current strategies for the prevention of ASCVD. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Oct 10;82(15):1499-1508. doi: 10.1016/j.jacc.2023.07.018.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The performance of the American College of Cardiology/American Heart Association pooled cohort equation (PCE) for atherosclerotic cardiovascular disease (ASCVD) in real-world clinical practice has not been evaluated extensively. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The goal of this study was to test the performance of PCE to predict ASCVD risk in the community, and determine if including individuals with values outside the PCE range (ie, age, blood pressure, cholesterol) or statin therapy initiation over follow-up would significantly affect PCE predictive capabilities. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The PCE was validated in a community-based cohort of consecutive patients who sought primary care in Olmsted County, Minnesota, between 1997 and 2000, followed-up through 2016. Inclusion criteria were similar to those of PCE derivation. Patient information was ascertained by using the record linkage system of the Rochester Epidemiology Project. ASCVD events (nonfatal and fatal myocardial infarction and ischemic stroke) were validated in duplicate. Calculated and observed ASCVD risk and c-statistics were compared across predefined groups. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: This study included 30,042 adults, with a mean age of 48.5 ± 12.2 years; 46% were male. Median follow-up was 16.5 years, truncated at 10 years for this analysis. Mean ASCVD risk was 5.6% ± 8.73%. There were 1,555 ASCVD events (5.2%). The PCE revealed good performance overall (c-statistic 0.78) and in sex and race subgroups; it was highest among non-White female subjects (c-statistic 0.81) and lowest in White male subjects (c-statistic 0.77). Out-of-range values and initiation of statin medication did not affect model performance. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The PCE performed well in a community cohort representing real-world clinical practice. Values outside PCE ranges and initiation of statin medication did not affect performance. These results have implications for the applicability of current strategies for the prevention of ASCVD.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793746</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.018>10.1016/j.jacc.2023.07.018</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793746</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Jose R Medina-Inojosa</dc:creator><dc:creator> Virend K Somers</dc:creator><dc:creator> Mariana Garcia</dc:creator><dc:creator> Randal J Thomas</dc:creator><dc:creator> Thomas Allison</dc:creator><dc:creator> Rajeev Chaudry</dc:creator><dc:creator> Christina M Wood-Wentz</dc:creator><dc:creator> Kent R Bailey</dc:creator><dc:creator> Sharon L Mulvagh</dc:creator><dc:creator> Francisco Lopez-Jimenez</dc:creator><dc:date> 2023-10-04</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice</dc:title><dc:identifier> pmid:37793746</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.018</dc:identifier></item><item><title> Nickel hypersensitivity as the cause of atrial fibrillation after patent foramen ovale closure: fact or myth?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37793154/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231005100804&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 4:ehad643. doi: 10.1093/eurheartj/ehad643. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37793154/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231005100804&v=2.17.9.post6+86293ac">37793154</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad643>10.1093/eurheartj/ehad643</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37793154</guid><pubDate> Wed, 04 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Anastasios Apostolos</dc:creator><dc:creator> Constantina Aggeli</dc:creator><dc:creator> Konstantinos Toutouzas</dc:creator><dc:date> 2023-10-04</dc:date><dc:source> European heart journal</dc:source><dc:title> Nickel hypersensitivity as the cause of atrial fibrillation after patent foramen ovale closure: fact or myth?</dc:title><dc:identifier> pmid:37793154</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad643</dc:identifier></item></channel></rss>